Kirk Allen Coleman is CFO & Secretary +1 at TFF Pharmaceuticals, Inc. (TFFP). They have made 10 open-market trades across 1 company since 2019, most recently 2024-07-03.
CIK 0001790624
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
5 open-market purchases totalling $34K since 2019, against 5 sales. Across 5 scored buys the stock is down 14.5% at ninety days, and 20.3 points behind the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| TFFP | 45,859 | $3K |
Shares reported on the most recent Form 4, priced at the 2024-07-08 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 60% | 40% | 20% |
| Avg Move | +4.0% | -3.1% | -14.5% |
| Alpha | +3.5% | -3.4% | -20.3% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TFFP | BUY | 2023-08-15 | 2023-08-15 | $0.25 | $5K | -1.5% | -2.6% | -43.6% |
| TFFP | BUY | 2023-03-10 | 2023-03-13 | $0.79 | $9K | -9.2% | -19.8% | -43.3% |
| TFFP | BUY | 2022-05-16 | 2022-05-17 | $4.51 | $8K | +20.2% | +5.1% | +15.0% |
| TFFP | BUY | 2021-09-16 | 2021-09-16 | $7.30 | $7K | +3.2% | -3.0% | -0.3% |
| TFFP | SELL | 2021-03-15 | 2021-03-17 | $17.05 | $85K | -19.5% | -26.9% | -32.1% |
| TFFP | SELL | 2021-02-16 | 2021-02-18 | $16.82 | $84K | -15.5% | -0.8% | -47.0% |
| TFFP | SELL | 2021-01-15 | 2021-01-20 | $17.50 | $88K | -17.6% | -13.7% | -43.1% |
| TFFP | SELL | 2020-12-23 | 2020-12-29 | $15.24 | $152K | +13.5% | +8.1% | -10.8% |
| TFFP | SELL | 2020-11-10 | 2020-11-13 | $15.12 | $227K | -6.6% | -16.5% | +8.4% |
| TFFP | BUY | 2019-10-25 | 2019-10-29 | $5.00 | $5K | +7.4% | +4.6% | -0.2% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.